These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29691399)

  • 1. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
    Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
    Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Badr M; Said H; Louka ML; Elghazaly HA; Gaballah A; Atef Abd El Mageed M
    J Cell Biochem; 2019 Mar; 120(3):3459-3466. PubMed ID: 30246355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
    Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
    DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.
    Pizzamiglio S; Ciniselli CM; de Azambuja E; Agbor-Tarh D; Moreno-Aspitia A; Suter TM; Trama A; De Santis MC; De Cecco L; Iorio MV; Silvestri M; Pruneri G; Verderio P; Di Cosimo S
    Breast Cancer Res Treat; 2024 Jul; 206(2):285-294. PubMed ID: 38689174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
    Pizzamiglio S; Cosentino G; Ciniselli CM; De Cecco L; Cataldo A; Plantamura I; Triulzi T; El-Abed S; Wang Y; Bajji M; Nuciforo P; Huober J; Ellard SL; Rimm DL; Gombos A; Daidone MG; Verderio P; Tagliabue E; Di Cosimo S; Iorio MV
    Cancer Med; 2022 Jan; 11(2):332-339. PubMed ID: 34921525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
    Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer.
    Yang T; Fu Z; Zhang Y; Wang M; Mao C; Ge W
    Biomed Pharmacother; 2020 Sep; 129():110465. PubMed ID: 32887021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2
    Decker JT; Hall MS; Blaisdell RB; Schwark K; Jeruss JS; Shea LD
    Biotechnol Bioeng; 2018 Oct; 115(10):2613-2623. PubMed ID: 29981261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
    Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.
    Du F; Yuan P; Zhao ZT; Yang Z; Wang T; Zhao JD; Luo Y; Ma F; Wang JY; Fan Y; Cai RG; Zhang P; Li Q; Song YM; Xu BH
    Sci Rep; 2016 Sep; 6():33825. PubMed ID: 27650797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
    Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
    Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN.
    Ye X; Bai W; Zhu H; Zhang X; Chen Y; Wang L; Yang A; Zhao J; Jia L
    BMB Rep; 2014 May; 47(5):268-73. PubMed ID: 24286315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.
    Rezaei Z; Dastjerdi K; Allahyari A; ShahidSales S; Talebian S; Maharati A; Zangooie A; Zangouei AS; Sadri F; Sargazi S
    Toxicol Appl Pharmacol; 2023 Sep; 475():116652. PubMed ID: 37557922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
    Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
    Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.
    Liu B; Su F; Lv X; Zhang W; Shang X; Zhang Y; Zhang J
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1039-1049. PubMed ID: 31482230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
    Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG
    Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.